EMERYVILLE, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc.. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has been issued a new patent (no. 10,646,456) by the United States Patent and Trademark Office (USPTO) that covers GOCOVRI (amantadine) extended release capsules Continue reading →

UCB Parkinsons Disease Treatment Market: Competitive Landscape This section of the report provides complete information about the various manufacturers in the market. Continue reading →

Parkinsons disease is a condition that causes the brain to become progressively more damaged over time, said the NHS. You could be at risk of the neurodegenerative condition if you realise that you've been passing more urine than normal. Parkinson's is caused by a loss of nerve cells in a specific part of the brain. Continue reading →

Sunovion Pharma is calling it quits on dasotraline, a dopamine and norepinephrine reuptake inhibitor it was developing for binge eating disorder and attention deficit hyperactivity disorder (ADHD). It withdrew New Drug Applications for both indications and stopped development of the program. Sunovion, a subsidiary of Japanese pharma Sumitomo Dainippon, first filed dasotraline for approval in August 2017, for the treatment of ADHD in children, adolescents and adults Continue reading →

May 14, 2020 07:00 ET | Source: Prevail Therapeutics Phase 1/2 Trial of PR001 for Parkinsons Disease with GBA1 Mutations Ongoing; Study Startup Activities Progressing for Phase 1/2 Trials of PR001 for Type 2 NeuronopathicGaucher Disease and PR006 for Frontotemporal Dementia with GRN Mutations Data Presentations Highlight Potential of AAV Gene Therapy Approach toSlow or Stop Neurodegenerative Disease Progression in Preclinical Models NEW YORK, May 14, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today reviewed recent business highlights and reported financial results for the first quarter ended March 31, 2020. We are excited to continue the clinical development of PR001 and are on track to report interim data for a subset of patients from our Phase 1/2 clinical trial of PR001 for Parkinsons disease with GBA1 mutations (PD-GBA) later this year. Continue reading →

Over 90% of target enrollment achieved to date in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in late 2020 Cash balance of $121 million expected to support planned operations into 2022 Conference call today at 5:00 p.m. EDT EVANSTON, Ill., May 14, 2020 (GLOBE NEWSWIRE) Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the first quarter of 2020 and highlighted recent progress across the companys clinical programs and pipeline of novel NMDA receptor modulators. Continue reading →